IRLAB Therapeutics AB (publ) announced that the company has entered into a grant agreement with The Michael J. Fox Foundation for Parkinson's Research (MJFF) and has been awarded funding amounting to over USD 2 million (exceeding SEK 20 million). In addition, MJFF provides support and access to leading expertise with extensive experience within Parkinson?s disease. The grant will be used to conduct the first-in-man Phase I clinical study of IRL757, a drug candidate in development as a novel treatment of apathy.

An effective treatment for apathy, both in Parkinson?s disease and in other neurological disorders, can transform the lives of millions of people who are left without an effective treatment. The grant was awarded under MJFF?s program ?Parkinson?s disease Therapeutics Pipeline Program.? This program seeks to advance preclinical and/or clinical testing of promising therapeutic developments that address unmet medical needs in people with Parkinson?s disease.

The program is set up to benefit therapeutics with clear potential to prevent, stop, or delay disease progression or to reduce the burden of daily symptoms. The drug candidate IRL757 has completed all preclinical studies and development work necessary to start Phase I. The clinical trial application (CTA) to be submitted to the regulatory authority is currently being prepared. More information will be shared as the program progresses.